Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

Mikiko Shimizu, Tsukasa Uno, Norio Yasui-Furukori, Kazunobu Sugawara, Tomonori Tateishi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The aim of this study was to compare possible effects of clarithromycin and verapamil as inhibitors of CYP3A4 on the pharmacokinetics of rabeprazole among CYP2C19 genotypes. Methods: A three-way randomized, double-blind, placebo-controlled crossover study was performed. Nineteen volunteers, of whom six were homozygous extensive metabolizers (EMs), eight were heterozygous EMs, and five were poor metabolizers (PMs) for CYP2C19, received three 6-day courses of either daily 800 mg clarithromycin, 240 mg verapamil, or placebo in a randomized fashion, with a single oral dose of 20 mg rabeprazole on day 6 in all cases. Plasma concentrations of rabeprazole and rabeprazole thioether were monitored up to 24 h after the dosing. Results: In the control phase, the AUC0-∞ values for rabeprazole and rabeprazole thioether were 1,005±366 and 412±149 ng.h/ml in homozygous EMs, 1,108±340 and 491±245 ng.h/ml in heterozygous EMs, and 2,697±364 and 2,116±373 ng.h/ml in PMs, respectively. There were significant differences (p<0.001) in the AUC0-∞ of rabeprazole and rabeprazole thioether among three different CYP2C19 genotypes. In the clarithromycin and verapamil phases, no significant differences were found in the pharmacokinetic parameters of rabeprazole compared with those in the control phase irrespective of CYP2C19 genotypes, whereas the AUC 0-∞ of rabeprazole thioether was significantly increased 2.8-fold and 2.3-fold in homozygous EMs (p<0.01), 2.0-fold and 2.0-fold in heterozygous EMs (p<0.05), and 1.6-fold and 1.9-fold in PMs (p<0.05), respectively. In each genotype group for CYP2C19, there were no statistical differences in the percent increase in those pharmacokinetic parameters between the clarithromycin and verapamil pretreatment phases. Conclusion: The pharmacokinetic parameters of rabeprazole were not altered by clarithromycin or verapamil irrespective of the CYP2C19 genotypes. However, this result shows that both clarithromycin and verapamil significantly influence the disposition of rabeprazole by inhibiting the oxidation of the thioether, since the AUC 0-∞ of rabeprazole thioether that has no effect on acid secretion increased. Therefore, the pharmacokinetic interactions between rabeprazole and CYP3A4 or P-glycoprotein inhibitors have limited clinical significance.

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume62
Issue number8
DOIs
Publication statusPublished - 2006 Aug
Externally publishedYes

Fingerprint

Rabeprazole
Clarithromycin
Verapamil
Pharmacokinetics
Genotype
Cytochrome P-450 CYP3A
Area Under Curve
Placebos
Cytochrome P-450 CYP2C19
Proton Pump Inhibitors
P-Glycoprotein
Sulfides
Cross-Over Studies
rabeprazole-thioether
Volunteers

Keywords

  • Clarithromycin
  • CYP2C19
  • CYP3A4
  • Rabeprazole
  • Verapamil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. / Shimizu, Mikiko; Uno, Tsukasa; Yasui-Furukori, Norio; Sugawara, Kazunobu; Tateishi, Tomonori.

In: European Journal of Clinical Pharmacology, Vol. 62, No. 8, 08.2006, p. 597-603.

Research output: Contribution to journalArticle

Shimizu, Mikiko ; Uno, Tsukasa ; Yasui-Furukori, Norio ; Sugawara, Kazunobu ; Tateishi, Tomonori. / Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. In: European Journal of Clinical Pharmacology. 2006 ; Vol. 62, No. 8. pp. 597-603.
@article{e45103bf8cc24983a8a86108fa422b82,
title = "Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes",
abstract = "Objective: Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The aim of this study was to compare possible effects of clarithromycin and verapamil as inhibitors of CYP3A4 on the pharmacokinetics of rabeprazole among CYP2C19 genotypes. Methods: A three-way randomized, double-blind, placebo-controlled crossover study was performed. Nineteen volunteers, of whom six were homozygous extensive metabolizers (EMs), eight were heterozygous EMs, and five were poor metabolizers (PMs) for CYP2C19, received three 6-day courses of either daily 800 mg clarithromycin, 240 mg verapamil, or placebo in a randomized fashion, with a single oral dose of 20 mg rabeprazole on day 6 in all cases. Plasma concentrations of rabeprazole and rabeprazole thioether were monitored up to 24 h after the dosing. Results: In the control phase, the AUC0-∞ values for rabeprazole and rabeprazole thioether were 1,005±366 and 412±149 ng.h/ml in homozygous EMs, 1,108±340 and 491±245 ng.h/ml in heterozygous EMs, and 2,697±364 and 2,116±373 ng.h/ml in PMs, respectively. There were significant differences (p<0.001) in the AUC0-∞ of rabeprazole and rabeprazole thioether among three different CYP2C19 genotypes. In the clarithromycin and verapamil phases, no significant differences were found in the pharmacokinetic parameters of rabeprazole compared with those in the control phase irrespective of CYP2C19 genotypes, whereas the AUC 0-∞ of rabeprazole thioether was significantly increased 2.8-fold and 2.3-fold in homozygous EMs (p<0.01), 2.0-fold and 2.0-fold in heterozygous EMs (p<0.05), and 1.6-fold and 1.9-fold in PMs (p<0.05), respectively. In each genotype group for CYP2C19, there were no statistical differences in the percent increase in those pharmacokinetic parameters between the clarithromycin and verapamil pretreatment phases. Conclusion: The pharmacokinetic parameters of rabeprazole were not altered by clarithromycin or verapamil irrespective of the CYP2C19 genotypes. However, this result shows that both clarithromycin and verapamil significantly influence the disposition of rabeprazole by inhibiting the oxidation of the thioether, since the AUC 0-∞ of rabeprazole thioether that has no effect on acid secretion increased. Therefore, the pharmacokinetic interactions between rabeprazole and CYP3A4 or P-glycoprotein inhibitors have limited clinical significance.",
keywords = "Clarithromycin, CYP2C19, CYP3A4, Rabeprazole, Verapamil",
author = "Mikiko Shimizu and Tsukasa Uno and Norio Yasui-Furukori and Kazunobu Sugawara and Tomonori Tateishi",
year = "2006",
month = "8",
doi = "10.1007/s00228-006-0152-9",
language = "English",
volume = "62",
pages = "597--603",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

AU - Shimizu, Mikiko

AU - Uno, Tsukasa

AU - Yasui-Furukori, Norio

AU - Sugawara, Kazunobu

AU - Tateishi, Tomonori

PY - 2006/8

Y1 - 2006/8

N2 - Objective: Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The aim of this study was to compare possible effects of clarithromycin and verapamil as inhibitors of CYP3A4 on the pharmacokinetics of rabeprazole among CYP2C19 genotypes. Methods: A three-way randomized, double-blind, placebo-controlled crossover study was performed. Nineteen volunteers, of whom six were homozygous extensive metabolizers (EMs), eight were heterozygous EMs, and five were poor metabolizers (PMs) for CYP2C19, received three 6-day courses of either daily 800 mg clarithromycin, 240 mg verapamil, or placebo in a randomized fashion, with a single oral dose of 20 mg rabeprazole on day 6 in all cases. Plasma concentrations of rabeprazole and rabeprazole thioether were monitored up to 24 h after the dosing. Results: In the control phase, the AUC0-∞ values for rabeprazole and rabeprazole thioether were 1,005±366 and 412±149 ng.h/ml in homozygous EMs, 1,108±340 and 491±245 ng.h/ml in heterozygous EMs, and 2,697±364 and 2,116±373 ng.h/ml in PMs, respectively. There were significant differences (p<0.001) in the AUC0-∞ of rabeprazole and rabeprazole thioether among three different CYP2C19 genotypes. In the clarithromycin and verapamil phases, no significant differences were found in the pharmacokinetic parameters of rabeprazole compared with those in the control phase irrespective of CYP2C19 genotypes, whereas the AUC 0-∞ of rabeprazole thioether was significantly increased 2.8-fold and 2.3-fold in homozygous EMs (p<0.01), 2.0-fold and 2.0-fold in heterozygous EMs (p<0.05), and 1.6-fold and 1.9-fold in PMs (p<0.05), respectively. In each genotype group for CYP2C19, there were no statistical differences in the percent increase in those pharmacokinetic parameters between the clarithromycin and verapamil pretreatment phases. Conclusion: The pharmacokinetic parameters of rabeprazole were not altered by clarithromycin or verapamil irrespective of the CYP2C19 genotypes. However, this result shows that both clarithromycin and verapamil significantly influence the disposition of rabeprazole by inhibiting the oxidation of the thioether, since the AUC 0-∞ of rabeprazole thioether that has no effect on acid secretion increased. Therefore, the pharmacokinetic interactions between rabeprazole and CYP3A4 or P-glycoprotein inhibitors have limited clinical significance.

AB - Objective: Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The aim of this study was to compare possible effects of clarithromycin and verapamil as inhibitors of CYP3A4 on the pharmacokinetics of rabeprazole among CYP2C19 genotypes. Methods: A three-way randomized, double-blind, placebo-controlled crossover study was performed. Nineteen volunteers, of whom six were homozygous extensive metabolizers (EMs), eight were heterozygous EMs, and five were poor metabolizers (PMs) for CYP2C19, received three 6-day courses of either daily 800 mg clarithromycin, 240 mg verapamil, or placebo in a randomized fashion, with a single oral dose of 20 mg rabeprazole on day 6 in all cases. Plasma concentrations of rabeprazole and rabeprazole thioether were monitored up to 24 h after the dosing. Results: In the control phase, the AUC0-∞ values for rabeprazole and rabeprazole thioether were 1,005±366 and 412±149 ng.h/ml in homozygous EMs, 1,108±340 and 491±245 ng.h/ml in heterozygous EMs, and 2,697±364 and 2,116±373 ng.h/ml in PMs, respectively. There were significant differences (p<0.001) in the AUC0-∞ of rabeprazole and rabeprazole thioether among three different CYP2C19 genotypes. In the clarithromycin and verapamil phases, no significant differences were found in the pharmacokinetic parameters of rabeprazole compared with those in the control phase irrespective of CYP2C19 genotypes, whereas the AUC 0-∞ of rabeprazole thioether was significantly increased 2.8-fold and 2.3-fold in homozygous EMs (p<0.01), 2.0-fold and 2.0-fold in heterozygous EMs (p<0.05), and 1.6-fold and 1.9-fold in PMs (p<0.05), respectively. In each genotype group for CYP2C19, there were no statistical differences in the percent increase in those pharmacokinetic parameters between the clarithromycin and verapamil pretreatment phases. Conclusion: The pharmacokinetic parameters of rabeprazole were not altered by clarithromycin or verapamil irrespective of the CYP2C19 genotypes. However, this result shows that both clarithromycin and verapamil significantly influence the disposition of rabeprazole by inhibiting the oxidation of the thioether, since the AUC 0-∞ of rabeprazole thioether that has no effect on acid secretion increased. Therefore, the pharmacokinetic interactions between rabeprazole and CYP3A4 or P-glycoprotein inhibitors have limited clinical significance.

KW - Clarithromycin

KW - CYP2C19

KW - CYP3A4

KW - Rabeprazole

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=33746446370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746446370&partnerID=8YFLogxK

U2 - 10.1007/s00228-006-0152-9

DO - 10.1007/s00228-006-0152-9

M3 - Article

VL - 62

SP - 597

EP - 603

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 8

ER -